No clinical benefit of rapid versus gradual tapering of immunosuppression to treat sustained BK virus viremia after kidney transplantation: a single-center experience.
Adult
Aged
BK Virus
Drug Administration Schedule
Female
Graft Survival
Humans
Immunosuppression Therapy
/ methods
Immunosuppressive Agents
/ therapeutic use
Kidney Transplantation
/ adverse effects
Male
Middle Aged
Multivariate Analysis
Mycophenolic Acid
/ administration & dosage
Polyomavirus Infections
/ diagnosis
Retrospective Studies
Tacrolimus
/ administration & dosage
Viremia
/ virology
BK virus
immunosuppression
kidney transplantation
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
14
09
2018
revised:
22
10
2018
accepted:
13
12
2018
pubmed:
20
12
2018
medline:
18
12
2019
entrez:
20
12
2018
Statut:
ppublish
Résumé
Immunosuppressive drug tapering is currently the recommended treatment of BK virus (BKV) viremia after kidney transplantation; however, its exact modalities remain unclear. We retrospectively compared two consecutive strategies in 111 patients with sustained viremia: a gradual monitoring/tapering group (GT, n = 57) before 2012 and a rapid monitoring/tapering group (RT, n = 54) after 2012. At viremia diagnosis, the dose of mycophenolic acid (MPA) and tacrolimus levels (T
Substances chimiques
Immunosuppressive Agents
0
Mycophenolic Acid
HU9DX48N0T
Tacrolimus
WM0HAQ4WNM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
481-492Subventions
Organisme : the National Fund for Scientific Research
Organisme : the Emmanuel Boussard Foundation
Organisme : the Day Solvay Foundation and the Centaure Foundation
Organisme : Société Francophone de Transplantation
Informations de copyright
© 2018 Steunstichting ESOT.